Tag: Opdivo
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
Adding nivolumab to neoadjuvant chemotherapy significantly increases pathological complete response rates
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
Approval based on noninferior pharmacokinetic exposures, similar effectiveness and safety to intravenous Opdivo
Entinostat + Nivolumab Yields Durable Results in Some Pancreatic Cancer Patients
Primary end point not met, but small subset of advanced pancreatic ductal adenocarcinoma patients showed durable responses
Long-Term Survival Benefit Seen for Nivolumab in Advanced Melanoma
Continued survival benefit seen for nivolumab plus ipilimumab and for nivolumab monotherapy versus ipilimumab monotherapy
FDA Approves Nivolumab as Adjuvant Treatment for Melanoma
Approval granted for patients aged 12 years and older with stage IIB/C disease
Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer
Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse
AACR: Adding Nivolumab to Neoadjuvant Chemo Slows Resectable NSCLC
Event-free survival prolonged and percentage of patients with a pathological complete response higher with addition of nivolumab
Nivolumab Combo Treats Advanced Esophageal Squamous-Cell Carcinoma
Overall survival longer in patients receiving first-line treatment with nivolumab plus chemo or nivolumab plus ipilimumab versus chemo alone
Adjuvant Nivolumab Slows Muscle-Invasive Urothelial Carcinoma
Disease-free survival was longer with adjuvant nivolumab in intention-to-treat population, for those with PD-L1 expression at least 1 percent
